Illumina, Inc. (ILMN) Earnings Call Transcript & Summary

July 31, 2025

NASDAQ US Health Care Life Sciences Tools and Services earnings 60 min

Earnings Call Speaker Segments

Brian Blanchett

executive
#1

Good day, everyone, and thank you for joining Illumina's call covering the second quarter of 2025. During this session, we'll go over the financial results we published following the close of the market, share some remarks, and then take your questions. You can find our earnings release in the Investor Relations area of illumina.com. With us today are Jacob Thaysen, our Chief Executive Officer, and Ankur Dhingra, our Chief Financial Officer. Jacob is going to share news about Illumina's businesses, and after that Ankur will walk through the company's financials. Every financial figure discussed on this call pertains to Core Illumina. If you'd like historical consolidated financials, please look at our earnings release and SEC filings. Before we go further, note that whenever we cite a year-over-year revenue growth figure in the prepared remarks, it's calculated on a constant currency basis — meaning currency exchange rate swings are stripped out. Please take a look at the GAAP reconciliation covering our non-GAAP measures; it's included in today's release and also in the supplemental data on our website. A recording is being made of this call, and the audio will be stored in the Investors section of our site. Regarding all forward-looking statements about financial results and commercial activity that we make on today's call, we intend for them to receive protection under the Private Securities Litigation Reform Act of 1995. For a clearer picture of the risks and uncertainties that might make actual results come in differently, please look at the filings Illumina makes with the Securities and Exchange Commission — among them our latest Forms 10-Q and 10-K. With that said, I'll hand things over now to Jacob.

Jacob Thaysen

executive
#2

Thanks, Brian, and good afternoon, everyone. During Q2, even though we saw a decline compared with the same period last year, our revenue landed at the upper end of the guidance range, coming in at roughly $1.06 billion. Meanwhile, strong execution by the team pushed profitability past what we had expected, delivering a non-GAAP operating margin of 23.8% along with non-GAAP EPS of $1.19. Taken together, these results show meaningful progress throughout the business and strengthen our belief that the underlying fundamentals are still robust. In Q2, we continued to see adoption of our NovaSeq X platform, with more than 50 placements, plus higher sales of high-throughput consumables, particularly among NovaSeq X users. As this transition keeps moving forward, we have maintained progress on our innovation roadmap, with key updates to our multiomics strategy that reflect disciplined execution of our long-term capital deployment plan. We feel encouraged by the strength in the clinical markets, which now represent about 60% of total sequencing consumables. Clinical has demonstrated greater resilience and in certain areas is surpassing expectations, which bolsters our confidence in the durability of clinical demand. We're observing this momentum across several clinical applications; in oncology, adoption of comprehensive genomic profiling keeps rising, and we're seeing growing interest in sequencing-intensive applications such as minimal residual disease, which positions us well for future clinical growth. In genetic disease testing, expansion continues to be powered by broadening national genome programs and wider adoption of whole genome and whole exome sequencing for rare diseases. In reproductive health, we're seeing growth in NIPT sample volumes, especially in the U.S., as more customers finish validation and ramp up clinical testing. We still believe the long-term clinical opportunity is significant, with NGS adoption rising as genomics becomes standard of care for therapy selection, early detection, monitoring, and extends into additional disease types. Although clinical demand has been encouraging, the research environment, especially in the U.S., remains constrained amid ongoing uncertainty around NIH funding. As anticipated, demand from this segment stayed soft in Q2, with certain labs postponing projects or pausing hiring because of worries about future grant availability. In the meantime, we are actively partnering with our customers to help them get through this period separately. In China, our ability to export instruments remains restricted. We continue talking with regulators to find solutions that support our long-term sustainable presence in the country, and we'll keep you updated on any material developments as we work through these near-term market dynamics. Our focus stays on disciplined execution and building the foundation for long-term success. That focus underpins our commitment to hitting our financial targets and delivering high single-digit revenue growth and expanding non-GAAP operating margin to 26% by 2027. We're moving toward these targets by delivering across our three key drivers: growing our core sequencing business, including continued progress with the NovaSeq X transition, scalable entry into multiomics to complement our sequencing platforms, and expanding our services, data, and software offerings to provide more integrated customer solutions. Taken together, these priorities underpin the wider strategy and vision we have for the industry — moving away from a cost per gigabase model toward providing the best possible biological insight at the lowest total end-to-end cost. Let me now turn to the headway we are making with our multiomics driver, which is focused on providing differentiated solutions that work in tandem with our sequencers. We have previously shared our capabilities in single-cell CRISPR-based Perturb-seq along with spatial analysis. In June, we advanced another step in proteomics through the acquisition of SomaLogic we announced from Standard BioTools. That deal broadens our footprint in affinity-based proteomics — a small yet rapidly expanding portion of the larger proteomics market — and extends the exclusive commercial relationship we have held with SomaLogic since 2021. SomaLogic occupies a key position in high-throughput proteomics. From small biological samples, the SomaScan assay is able to analyze more than 9,500 unique human proteins, yielding deep, actionable insights for drug discovery, diagnostics, and health monitoring. What distinguishes their technology is proprietary SOMAmer binding — highly precise affinity reagents that attach to specific proteins with sensitivity, scalability, and reproducibility that have no equal. Compared with other methods, this approach provides broader coverage while cutting the time and cost of deep proteomics analysis. Bringing SomaLogic into Illumina extends a partnership that has existed for a long time. As our collaboration moved forward, our conviction in their technology grew deeper, and we identified a clear chance to speed up innovation by folding their capabilities into our innovation engine. Leveraging Illumina's product development expertise and worldwide commercial reach, we will scale their technology more quickly, broaden customer adoption, and realize greater operational efficiencies. For Illumina, SomaLogic represents a strong strategic fit. When their technology is paired with our platforms, it offers a highly successful, scalable, and cost-efficient solution for proteomics discovery. By integrating proteomics more deeply into our ecosystem, we expand our capacity to deliver greater biology insights through our end-to-end workflows; this strengthens the value proposition of the NovaSeq X and opens the potential to extend SomaLogic technology into other multiomics applications, including single cell and spatial. With this addition, we are moving toward a more comprehensive multiomics portfolio that spans DNA, RNA methylation, and now proteomics. We expect the transaction to close in the first half of 2026, following receipt of the required regulatory approvals. We look forward to welcoming the SomaLogic team to Illumina and to expanding the impact of proteomics together as we push forward key elements of our multiomics strategy. Strong momentum is also evident across our recent platform launches. The MiSeq i100 Plus, our newest benchtop sequencer, is one example. Since its launch late last year, we have placed more than 500 instruments, and we are now seeing customers order additional units after only a few months of use. Customer feedback on the MiSeq i100 platform continues to be very positive. Customers describe it as a game changer, pointing to faster turnaround times, ease of use, and room temperature shipping and storage arrangements — all features that make sequencing more accessible for labs working in a wide range of resource settings. This cuts down how much labs depend on central facilities, speeds up how quickly diagnoses come back, and hands customers more control when they run oncology, infectious disease, and various other clinical applications. Such capabilities hold particular appeal for labs bringing NGS in for the very first time, and likewise for those operating in emerging markets. Right now the MiSeq i100 platform handles 18 validated workflows, among them nine that are fully integrated all the way from library prep through analysis; integration at that level speaks to a wider shift in our innovation approach, one rooted in richer customer understanding and tight cooperation across the development process. MiSeq i100 establishes a fresh benchmark for where Illumina innovation is headed, tuned for comprehensive end-to-end workflows that bring down adoption hurdles and produce top-tier insights at scale. Before passing things to Ankur, let me take a moment to lay out how we see the rest of 2025. The momentum behind our Q2 results and the strides on our innovation roadmap give us encouragement, and our attention stays fixed on executing with discipline. Even so, we keep approaching the year's second half carefully, since funding uncertainty persists in the U.S. research market. With that in mind, we are lifting our guidance for total company revenue growth along with total reported revenue, non-GAAP operating margin, and non-GAAP EPS, which mirrors solid execution and operational discipline throughout the organization. I'll now hand things to Ankur so he can walk through our results and outlook in greater detail before we open up Q&A.

Ankur Dhingra

executive
#3

Thank you, Jacob, and good afternoon to all of you. I'll walk you through how we performed financially in the second quarter, offering additional detail on revenue, expenses, earnings, along with updates regarding our balance sheet and capital deployment, and after that I'll discuss what we expect looking ahead. Before diving into specifics of the financial results, allow me to give a big-picture perspective on where the second quarter stands in Q2; we continued making headway against our long-range objectives and turned in results that came in above what we had anticipated for the quarter. Although revenue declined compared with the same period a year ago, it landed at the upper end of our guidance range, fueled by momentum in high-throughput consumables. We achieved robust organic margin expansion along with EPS of $1.19, which comfortably surpassed the ceiling of our guidance range. As we had expected, research customers, particularly academic and government customers in the U.S., remain cautious in how they allocate their budgets given funding limitations. The patterns during Q2 largely matched those observed in the latter portion of Q1; conversely, our clinical customers keep putting money into broadening their portfolio and expanding the scale of currently marketed tests. Our Greater China business performed a touch above the guide, and customers there remain highly engaged and supportive of Illumina's differentiated technology. Consumables sales have proven resilient, and talks with the pertinent authorities are ongoing. Now allow me to walk through specifics of the financial results. Revenue for the second quarter reached $1.06 billion, representing a decline of roughly 3% versus a year earlier on both a constant currency and reported basis. Greater China revenue totaled $63 million, coming in a bit above expectations and reflecting a $12 million drop relative to the second quarter of 2024. With Greater China excluded, Illumina revenue fell approximately 2% on a constant currency basis. Sequencing consumables revenue amounted to $740 million, roughly flat compared with a year ago and up about 6% quarter over quarter on a reported basis. High-throughput consumables increased on both a sequential and year-over-year basis, helped by sequential growth exceeding 10% in NovaSeq X consumables revenue. Robust expansion within the clinical segment, which today accounts for approximately 60% of our total sequencing consumables, stems mainly from wider adoption of comprehensive genomic profiling as well as growing momentum in sequencing-intensive applications such as MRD, positioning us favorably for growth down the road. The X transition keeps moving forward, as we've disclosed that more than 80% of sequencing volumes among our research customers have already shifted to X, while those customers keep confronting budget limitations. Our clinical customers remain engaged in the transition, navigating validation efforts and weighing their investments between tests already on market versus developing new ones. On the clinical X transition, we got to about 55% during the quarter. In Q2, close to 69% of high-throughput gigabases were shipped, and roughly 44% of revenue from high-throughput consumables came from the NovaSeq X series. We're still moving forward with the high-throughput transition framework we laid out earlier, and if we keep up this pace, we expect that near the end of 2025, about 50% of high-throughput revenue and around 75% of gigabases shipped will come from a NovaSeq X series. We think the clinical segment will drive this as customers expand their sequencing activity on the NovaSeq X. Total sequencing Gb output from our connected high and mid-throughput instruments rose by over 30% year-over-year, with strong momentum in clinical but softer growth from research customers. Even though it doesn't predict near-term revenue, looking at gigabase output on connected instruments gives us a directional sense of the underlying applications, demand, and utilization levels for our connected instruments and sequencing consumables. Revenue came in at $96 million, down about 18% year-over-year in Q2, as we felt the impact of tight budgets among our high and mid-throughput research customers. The funnel pipelines stayed intact, but decisions took longer among our customers. About 60% of the X's placed in Q2 went to clinical customers. On the low-throughput side, the MiSeq i100 Plus launch is going quite well, and customers have given positive feedback on the platform and are looking forward to the MiSeq 100 base model launch next month in Greater China. Our instruments business dropped approximately 40% because of exportation restrictions. Sequencing service and other revenue was $136 million, down roughly 5% year-over-year, in line with expectations. The decline was primarily from the timing of certain strategic partnership revenues last year tied to the AGD consortium. If you exclude those items, our core services and informatics business grew high single digits as we move to the rest of Illumina P&L. Non-GAAP gross margin was 69.4% for the second quarter, up 200 basis points quarter over quarter and stable year-over-year; we saw favorable product mix in our sequencing business, driven by a high consumables revenue mix. Also, our ongoing Operating Excellence action plan initiatives helped improve gross margin performance this quarter. Tariffs had a partial effect this quarter, with a net impact of about 110 basis points on our gross margin. In Q2, non-GAAP operating expenses were $484 million, down approximately 6%, or $32 million, year-over-year. That shows the effect of actions we've taken toward our long-range commitments of expanding margins while prioritizing key growth investments. Thanks to our discipline, we didn't see the usual seasonal rise in OpEx that happens after Q1. Non-GAAP operating margin was 23.8% in Q2, up 160 basis points year-over-year. Operating profit grew approximately 4% year-over-year on lower revenue, reflecting increased operating leverage from the improved cost structure. Now turning to the items below the line in our results: non-GAAP other expense, mostly made up of net interest expense, came to $10 million, while our non-GAAP tax rate stood at 22.2%. It's worth noting that the tax legislation passed recently didn't affect our Q2 tax rate, since it became law only after the quarter closed. Average diluted shares totaled roughly 157 million, about 2 million fewer than the prior quarter, reflecting a higher level of share repurchases net of dilution from employee equity awards. On the whole, non-GAAP EPS reached $1.19 per diluted share, up 9% from a year earlier and comfortably ahead of our guidance range. Now on to cash flow, balance sheet, and capital allocation matters for the quarter. Operations generated a strong $234 million in cash flow, capital expenditures totaled $30 million, and free cash flow came to $204 million. During Q2, we bought back roughly 4.5 million shares of Illumina stock, spending $380 million at an average price of about $85 per share. As part of the roughly $800 million authorization still available when the quarter ended, we plan to keep repurchasing additional shares throughout the year. We also signed a definitive agreement with Standard BioTools, under which Illumina will purchase SomaLogic and certain other specified assets for $350 million in cash due at closing, plus as much as $75 million tied to near-term performance-based milestones and royalties; the transaction should close during the first half of 2026, pending regulatory approvals; we stay intensely focused on making the most of our growth opportunities via capital allocation initiatives, with strong confidence in their contribution margins to a long term strategic plan.

Ankur Dhingra

executive
#4

When the quarter ended, we had about $1.16 billion in cash, cash equivalents, and short term investments, and our gross leverage stood at roughly 1.7x gross debt to last 12 months EBITDA. Turning now to what we expect for 2025: the press release likely caught your attention, since we've lifted both our operating margin and EPS outlook for 2025, while keeping est of the World constant currency revenue growth within the range we gave back in May. Revenue expectations from China have gone up as well. Let me walk through the details, beginning with revenue: for the Greater China region, our revenue guidance is moving up by $25 million at the midpoint, landing at approximately $200 million for the year. Even though we still can't ship instruments into that country, consumables demand has held up, and the customer backing we've received is strong—we expect that to carry over, at least partially, into Q3. Outside that market, our revenue outlook for the rest of the world stays the same: 0% to 2% growth in constant currency. As a result, taking FX movements into account, we now expect Illumina's total constant currency revenue to fall somewhere between -0.5% and -2.5%. For reported Illumina revenue, our updated outlook is $4.23 billion to $4.31 billion. Turning to rest-of-world product assumptions, we now anticipate sequencing consumables growth of 1% to 3%, improved from flat to 2%, reflecting robust sequencing activity among our clinical customers and bringing our guidance in line with reported revenue to capture pricing actions' impact. For rest-of-world sequencing instruments, we are reducing our expectations to a year-over-year decline of 4% to 6%, pricing actions included; this reduction stems mainly from caution among our research customers observed late in Q2. Even though we anticipate a modest rise in demand for NovaSeq X instruments and growth in low throughput from MiSeq i100 placements, mid-throughput has shown softness. Now, continuing down the income statement, the Illumina team, as shared before, is advancing well on operational excellence programs and reducing our cost structure. Our focus on costs, together with higher revenue from Greater China's strong performance and beneficial FX rates, has enabled us to lift our operating margin outlook by about 50 basis points, to a range of 22%-22.5%. Additionally, new legislation passed earlier this month permits U.S.-based R&D spending to be tax deductible. Considering how large Illumina's U.S. When it comes to the R&D base, we think this bill will help our tax rate in 2025 and afterward. Our FY25 tax rate is now projected at around 20%. Because we've been buying back more shares, we're now looking at a FY25 WASO of roughly 157 million shares. Putting all of this together, these changes let us lift our EPS guidance by $0.25 at the midpoint, bringing it to a range of $4.45 to $4.55. Tax changes account for roughly $0.10 of that increase, China contributes about $0.10, and the remaining amount comes from FX along with better operating margin. To sum up, looking at the middle of the range, our revised FY25 outlook reflects a $50 million increase in revenue, a 50 basis point lift in op margin, and EPS that's $0.25 better. Now moving to Q3 of 2025: for that quarter, we expect revenue excluding Greater China to be up 1% to 2% year over year in constant currency, while Greater China revenue comes in somewhere between $35 million and $45 million. Put together, Illumina's total constant currency revenue should fall within a range of 1.5% to 2.5%. As for Q4, we're looking at a non-GAAP operating margin of about 22%, a non-GAAP tax rate around 16%, WASO near 155 million shares, and non-GAAP EPS in the $1.15 to $1.19 range. That suggests a rise in revenue, with about half attributable to typical seasonality in instrument purchases. The rest, we expect, will stem from a mix of data service offerings such as AGD and new products such as our proteomic solution. To wrap up, I want to share my ongoing gratitude to the Illumina team for their unwavering dedication to execution and for delivering yet another quarter of progress toward our near and long term objectives, which is enabling us to lift this year's guidance. Thanks for being with us on today's call. I'll now ask the operator to open the line for Q&A.

Vijay Kumar

analyst
#5

Hi everyone, I appreciate you answering my question, and congratulations on the results and the way you executed. My single question concerns the change to guidance. Could you walk us through a bridge? It seems instruments declined by $25 million, China gained $25 million, and perhaps some of that was FX. What else is there? Were there any shifts in consumables? Is anything else moving on the microarrays side? Ankur, I believe you brought up new products, and Jacob, perhaps you could discuss the pipeline and new offerings. How significant is this? In my view the street hasn't paid sufficient attention to the pipeline, but might it matter more in the coming year? Thanks.

Jacob Thaysen

executive
#6

Vijay. Thanks so much, and I appreciate you recognizing the strong quarter we delivered. You are completely correct. Our pipeline holds a great deal, and actually, I recently reviewed input from our early access customers regarding Constellation, 5- base, and our spatial solutions, and I would describe the response across all three products as extremely positive. Our customers are delighted to gain access to these ahead of time, and as you pointed out to me previously, at this stage we are more likely to be launching and gathering customer feedback; we involve them quite early so that we can collect their input, while also letting them become enthusiastic and begin considering publications as well as pursuing grants; we expect that to begin making a difference as early as 2026. We are confident this will contribute additional growth beginning in 2026 and continuing afterward. Ankur.

Ankur Dhingra

executive
#7

Yes, thank you Jacob, and thank you too Vijay. Regarding what you asked about the factors driving the guide, allow me to break it down into a couple of distinct parts depending on which aspect you meant. First, the guide moved higher because of FX and also because of growth in China on a total basis. Looking at it from the angle of the rest of the world, we're bringing down our outlook for instrumentation, and that's based purely on what Q2 showed us, mostly out of the research market. The pipeline moved through over the course of the quarter. At the same time, what balances that out on the instrumentation side is consumables for the rest of the world. Our expectations for consumables are going up, since that business performed really nicely in Q2 and given how we see the pipeline shaping up for the remaining part of the year. The other piece of your question had to do with services. There are a couple of elements there. The first is this data services business we've discussed. As you may remember, for the entire prior year we had roughly $80 million to $90 million across the full year on that data services side, coming out of our AGD consortium, and it leaned somewhat toward the first half of last year — which, if you remember, is why I commented on our earnings call one quarter ago that the comparison turns favorable for us in the back half of this year. We expect some business in that area, plus possibly some of the new services we intend to roll out here in the back half of the year. Should everything go according to plan, we'll address what we expect from those services when we reach our 2026 guidance.

Subbu Nambi

analyst
#8

Hello everyone, and thanks for allowing me to ask. Have you observed any shifts in how customers are acting because they expect more competition? What steps are you taking to get ready for that scenario? When we examine the Roche platform, one characteristic that appears difficult for your company to equal given your present engineering is likely the speed of completing a run. To expand on what Vijay asked, do you have anything in development that could help you compete better against a high-throughput platform regarding how quickly results are delivered?

Jacob Thaysen

executive
#9

Yes. Subbu, we certainly devote considerable effort to considering our rivals, yet I'd say we devote even greater effort to considering the people who buy from us and how we keep delivering value to them daily. I recognized this when I joined the company—that in my view we had room to improve how we connect with those customers. Like I said earlier, involving them through early access to what we build, giving them visibility into the roadmap, and so forth. That's roughly where our primary attention goes: guaranteeing we constantly back our buyers, that we keep bringing new ideas forward, that within this sector we hold the biggest commitment and the biggest spending budget when it comes to research and development, and as you might expect, we likewise have many initiatives underway. We've publicly discussed portions of what we're developing in the multiomics area, though obviously certain details remain private. We're additionally developing our instruments to tackle what we see as the primary expanding markets ahead, especially clinical applications, and also decentralized settings; we're examining the features, and we collaborate extensively with our buyers to learn which features matter most to them. You're correct that certain groups of customers want results quickly. That's a specialized segment in the NICU, where getting an answer out rapidly is essential, and you might sacrifice things like how simple it is to operate or possibly the sequencing accuracy. When you consider the overwhelming majority, in that case we're targeting situations where running overnight makes complete sense and still delivers every piece of data you need. That's the segment we're aiming at, and our platform is highly capable of handling that portion of the business. Ultimately, what we'll prioritize is delivering the best possible insight at the fewest total steps, no matter which customer we're serving.

Puneet Souda

analyst
#10

Yeah, hi Jacob, Ankur, I appreciate you both fielding my questions. I'm curious whether there was any pull forward among customers during the quarter. We'd been picking up that certain customers were building inventory in advance of the tariffs in May and April too. On the clinical side, what are you picking up from some of your bigger customers? The rate at which clinical transitions are occurring is sluggish, though that aligns more closely with your expectations for the X transition. I'm just attempting to get a handle on what some of the bigger customers, ones with large fleets of X, large fleets of 6,000, are saying regarding moving to X. I suppose what I'm really asking is whether that shift could occur aggressively in the second half. What are you picking up from those customers? Thank you.

Jacob Thaysen

executive
#11

Yeah, I'll begin by tackling your first point regarding whether any pull forward occurred. We didn't see any. To the degree there was anything, it was a typical quarter. What we are observing is that our backlog has grown. Initially, when we brought the X to market, clearly a lot of customers had to trial it and begin validating, and it wasn't clear what volume they'd need or when they'd make the switch. In that regard, from an ordering standpoint, it was more hand to mouth, as the saying goes. These days, a large number of our customers are quite at ease operating the X and doing so in manufacturing mode or in production mode. That likewise means their planning improves, which is now reflected in a bigger backlog. That matches where we anticipate it should be. As you pointed out, we keep witnessing the shift toward the X taking place. If you examine things at the level of each individual customer, naturally, every customer has validations they wish to carry out, and they want to be certain they can do so. You can observe that a great many of our clinical customers are expanding extremely quickly; they have no desire to jeopardize that expansion; they possess a very well-defined program for the timing of their switch. There's no sudden cliff where everything migrates in a single quarter or another quarter. It will occur when a customer decides the moment has come for us to make the change, and then you'll witness that customer swiftly moving over one assay or several assays. We anticipate that unfolding smoothly going forward. There may be a quarter that comes in somewhat higher, perhaps a quarter that's a bit elevated from a transition standpoint. We don't anticipate any cliff materializing at any point in the near future.

Doug Schenkel

analyst
#12

Good afternoon, and thanks for taking my question. From what I can tell, your guidance suggests roughly 2 points of revenue growth will come in the fourth quarter, leaving China out, and that would mark the fastest pace in no less than two years — if I'm understanding that correctly. So my first question: am I reading that right? And if I am, what does it mean when we consider some of the pricing challenges and other matters you've spent the last couple of years addressing? Then, second, building on that — and let me offer three quick observations before I ask: first, as we exit 2025, global research will account for under 40% of sales, and that share could still shrink given the NIH situation in 2026. Even with the encouraging news from the Senate today, and even allowing that things may not turn out as bad as people fear, on a weighted basis that might create a 2 to 3 point headwind next year. Second, China may stay under pressure, though it could fall to roughly 2% of sales by the time the year ends. Good guy or bad guy, it's becoming small. Third, one unmistakable piece of good news, an unmistakable good guy, is clinical, which will represent over 60% of sales, expanding at a double-digit rate with substantially greater volume partly offset by pricing. On a weighted basis, that might deliver six points of growth. Meanwhile, you could face a 2 to 3 point growth headwind from the research end market. When I blend all this mathematically, it appears you ought to be able to grow core revenue in the low single digits, perhaps even the mid single digits, excluding China next year. Does that framework seem reasonable as things stand today? Is there anything else you'd like us to consider while we update our models? Anything on possible upside from pipeline, or reasons for caution regarding competition — any of that would help on all these fronts. Thank you.

Jacob Thaysen

executive
#13

Yes, thanks. That question ran quite long just to essentially ask whether I'm giving guidance for 2026, which I'd say comes a bit too early. Our focus right now is very much on executing on the business for 2025, yet we do see solid momentum. What I'll leave you with is this: as we also said last year when we released our strategy, we anticipate — both for ourselves and in our expectations — that the X transition serves as the primary growth engine over the coming period, and it's what will allow us to begin stepping into growth. We expect 2026 to outperform 2025, and 2027 to outperform 2026. That's essentially how the logic works. As you noted too, there are naturally ins and outs, but our primary growth engine going forward will also be in the clinical space. I believe the proof from every one of our clinical customers, in terms of what they're achieving, backs that up strongly. Dx is still what we see as the primary engine behind this. On top of that, we anticipate multiomics continuing to contribute at minimum 1% point of growth as we move into 2026 and 2027, and likely a bigger contribution at the 2027 stage. That's the situation as it stands; we genuinely feel the outlook ahead is quite thrilling. The markets we serve are big. Sure, there will be ups and downs, and our attention will go to the portion of the business entirely within our control, which naturally accounts for over 95% of what we do, located outside China.

Eve Burstein

analyst
#14

Hello there, and good afternoon. I really appreciate you taking my question. To build on something you mentioned in one of your responses — you noted that you hadn't observed any pull forward ahead of tariffs. What about China consumables? How much of that, if any, got pulled forward, perhaps because existing customers were concerned they might not be able to purchase additional sequencing consumables in the near future? And on that note, would it be fair to characterize your raised guidance for China as potentially tied specifically to 2025, rather than a signal of a better outlook for 2026?

Jacob Thaysen

executive
#15

Yes. Eve, let me return to the topic of China. Although I prefer not to devote much time to a very small portion of our business, just for context, here's where things stand. What I'm seeing makes me very happy. Jenny, who serves as our General Manager in China, along with the Chinese team — the work they're doing is tremendous in supporting our customers there. It also says a great deal that we keep seeing substantial interest from our customers. The feedback coming our way from customers is that they truly want us to remain in China, given the high quality we deliver, the innovations, and naturally the ecosystem, which matters greatly to Chinese customers as well. We are seeing considerable interest from them. As you pointed out too, under the present circumstances, the overall situation cannot be sustained. We keep working extremely diligently with the regulators to reach a resolution. When it comes to pull forward, I believe we saw a bit of that possibly in Q1, during the first quarter, but at this moment we aren't seeing it. I'd say we're now more at a natural run rate for the business, and that's what we have. We feel good about the way we've guided for China, yes.

Ankur Dhingra

executive
#16

Eve, there are just a few points I'd like to make. Appreciate it, Jacob. When we look at markets beyond China, there really hasn't been much of a pull forward. Orders came in at a solid level. Keep in mind that for our biggest segment, which centers on high-throughput consumables on X, shelf life is limited. So a meaningful pull forward simply isn't possible. We did book orders for shipments down the road, but that doesn't mean shipments shifted into Q2. On your second question regarding China, like Jacob mentioned, talks are ongoing, though the guidance increase for Q3 in China — you're correct — isn't something we view as a long-term matter. It applies to the quarter we're in. As Jacob is saying, our working assumption is that we're talking with the authorities in order to reach a constructive resolution over the long run.

David Westenberg

analyst
#17

Hello, and thank you for fielding my question. Congratulations on a solid quarter. I'd like to remain on the topic of the clinical cliff. Clinical has actually been a fantastic market for you over the past 3 years compared with academics, though perhaps some investors harbor a bit of doubt. Could you discuss the spending trends you've observed among clinical customers, and perhaps even separate out those who have been with you from the very start, in year one, and describe what their spending has looked like as we head into Q3? Is there any detail available regarding how customers transition — for instance, whether they move their whole fleet or just part of it — and how that affects clinical spending? Second, regarding this transition, you also noted that clinical only rose from 43% to 44% of the volume on X. If X sees a large increase in the back half of the year fueled by clinical, why wouldn't revenue decline there? Thank you for taking the question.

Jacob Thaysen

executive
#18

Alright. Hey, Dave. Appreciate that. Let me begin by framing things a bit, and then Ankur can dig deeper into the specifics. You're completely correct that the clinical portion of our business is extremely strong. I genuinely think this will remain a powerful market force for the foreseeable future, which extends quite far ahead. These markets are highly attractive; we keep seeing many opportunities in oncology. As everyone knows, there's a great deal happening around therapy selection, but we're only now beginning to open things up for minimal residual disease testing. Ultimately, screening will also become significant at some point. That represents a long horizon for opportunity within clinical oncology. In fact, in genetic disease testing, including rare diseases and other areas, we observe substantial interest both in broadening rare disease testing to a wider segment of the population — rare diseases aren't as uncommon as one might assume — and in moving toward newborn screening, which will be a major opportunity down the road. We fully agree there are enormous opportunities in the clinical space, and it will be a primary driver for Illumina going forward. Now, as you said, getting into the specifics of what a transition looks like, I'll begin by noting that on the whole, most customers, if they've been using the 6000, decide that when they move to the NovaSeq X, they usually aren't merely attempting to lower the cost of the test — they're actually attempting to broaden the test. This is an extremely and highly competitive environment. For many of our customers, it's about remaining competitive. What you do is give your clients superior assays, and you achieve that by broadening them and delivering additional insights. Next, some customers are going to remain with the 6000 right up until the assay reaches end of life — a point they figure is maybe 2 years away. Looking at it financially, putting in the effort and the money to move over to the X simply isn't worthwhile for them. That's the transition at its most basic level. Ankur, do you have.

Ankur Dhingra

executive
#19

I'd say that's pretty solid, Jacob. This isn't something that flips overnight; you need validation, and you move through it one step at a time. Dave, we've observed this before too — the shift from one quarter to the next hasn't followed a straight line. It comes in lumps. Certain quarters bring movement, others bring none. I'm not putting much weight on this, and I'm not saying a major material shift is suddenly right around the corner in the coming 2 quarters either. What we're still aiming for is that on the whole, volume — 75% of it — moves over to X during the back half of the year, or in this year's half two. Judging by what this quarter showed us, it could lean more toward the later portion of Q4, though again, it'll be lumpy from quarter to quarter.

Tycho Peterson

analyst
#20

Hi, thank you. When it comes to your instrument guidance in general, what's your view? How are we supposed to think about how X placements will trend over the remainder of the year? The reason I ask is that X's share of high-throughput revenues rose by just 1%. During the quarter just reported, that figure moved from 43% up to 44%. What gives us confidence that you can reach 50% by the time the year closes? Could you also tell us what share of customers are currently achieving 30B reads? I'm aware you rolled out software to make that possible, but I'd imagine that carries some consequences for consumables. As for operating margins, they came in far above what we anticipated. Did tariff unwind account for all of that, or did the cost out programs contribute, or was it both? Thanks.

Jacob Thaysen

executive
#21

Hi Tycho, were you referring to the 10 B reads, or, apologies, which question was that? 30B?

Tycho Peterson

analyst
#22

Yeah, the 1.3 version of the software that came out last year. The key thing I want to ask about is X placements.

Jacob Thaysen

executive
#23

I'll begin with the X placement topic. I also want to point out that our Q4 placements were really strong, exceeding 90, and then in Q1 we likewise reached 60 placements. A lot of the customers who bought and had Xs installed continue to use them — particularly on the clinical side, where the great majority of instruments went — and they're still using them and feeding them into their production. You'd want to see a meaningful effect from that in the back half of the year too. There won't be any cliff whatsoever, but the shift from the X transition will keep showing up through the remainder of the year. Consistent with our earlier guidance, we continue to expect roughly 50 to 60 instruments placed each quarter on average, and there's potential for additional instruments to go in during Q4, depending on whether budgets materialize as we hope. Regarding the flow cell, you're correct that the 1.3 software release involved substantial effort on our part to enhance the customer experience, and we'll keep at it. Improving yield in the 25B was part of that effort as well, though at this moment we're not making a commitment to a 30B.

Ankur Dhingra

executive
#24

Let me take the operating margin piece. Tycho, most of the gain in operating margin came from the cost measures, a portion of which were from last year, with the rest tied to steps we took early in this year, now starting to show up in the P&L. On tariffs, work has begun and we are starting to see a route toward lessening their impact. Little of that showed in our Q2 results as such. Our view is that in the back half of this year and definitely in early 2026, some of those benefits will start to appear, though not in Q2. As I mentioned on my call, we expect OpEx to roughly stay at that reduced level, which reflects close to $100 million in annualized improvement in OpEx at present, based on what Q2 shows you. That is a structural shift we have made in our cost structure, and it clearly ought to position us well for significantly better operating leverage down the road as revenue gets back to growing.

Kyle Mikson

analyst
#25

Yeah, hey everyone, appreciate you taking the questions. Solid quarter against the growth framework. Jacob, you mentioned this before. My recollection is volume growth somewhere in the 20%-30% range, with price declines also in the mid teens. I was just curious whether you could break down how much of that volume growth comes from clinical versus research. I know some figures and assumptions came up earlier. Would really like to hear what you think about that. Do you have enough room to cut price further if needed? Should new competitive threats show up, is that the moment Roche sort of reveals its pricing? Thanks.

Jacob Thaysen

executive
#26

Yeah; as we also said in prepared remarks, we keep seeing robust volume growth among our customers. If you look a bit more closely at this quarter, it ought to be clear as well that clinical outperformed the research segment. That matched expectations given all the changes involving NIH and other funding sources at the moment. While the gap has been somewhat wider this time, we anticipate clinical growth will remain the stronger of the two over the long horizon, mainly because the opportunity there is bigger. We genuinely believe that once multiomics begins to truly accelerate, that will also help lift the research side; that may come somewhat later within our strategic planning period here. On pricing, we remain very stable, and we are inside the anticipated range for the price decline we are experiencing in terms of what we can do on pricing. Look, we want to be sure we always grasp our customer and what they require to get the most out of their performance. Naturally, we are also discussing whether new applications could be unlocked by taking a differentiated approach to pricing. That is something we will always pursue with our customers. I think there's an expression out there that some competitors might have lower pricing, but in most cases Illumina has the best cost structure; we will always be capable of competing if we decide to do so on pricing.

Dan Arias

analyst
#27

Hey everyone, I appreciate you taking the questions. My phone was acting up. Ankur, sorry if this was covered earlier, but could you speak briefly about how GV grows going forward along with high-throughput? Can we remain within that 30% band during 3Q and 4Q? And if that's the case, should we still feel comfortable with the 2026 framework you previously shared — roughly mid-20s GV growth, offset by a pricing headwind in the mid teens? Thanks.

Ankur Dhingra

executive
#28

All right. Yeah, that's a fair question, Dan. Typically this comes up as part of the script. Let me address two points. First, broadly speaking about connected instruments — when we examine our runs on those connected instruments within high-throughput, overall that figure exceeded 30%. What we observed across the quarter was that clinical, as we've discussed, stayed very robust. On the research side we did notice some deceleration, particularly within the broader U.S. research area, which matched expectations considering all that is happening there regarding the funding landscape. Going forward, do I expect it can remain above that 30% threshold? We believe so. Specifically clinical, and also at minimum the rest of the world excluding China — although China hasn't been connected — remaining above 30%, there's still a number of structural tailwinds arriving, particularly with MRD being such an appealing space. We also observed across the quarter solid progress on the reimbursement front for genetic disease testing and beyond. We're witnessing whole genome adoption picking up momentum even from a reimbursement standpoint. There are favorable structural developments, particularly on the clinical side, capable of fueling GB growth on the research side. I believe our proteomics play ought to be net new incremental from a sequencing standpoint. As we finalize the deal or roll out the IPP here, that tool likewise seeks to carry some proteomics into the sequencing portion of the business; as a market it has always leaned heavily toward mass spec, yet by pulling that into the sequencing ecosystem, that's one more additional area we're incorporating into the sequencing ecosystem.

Jacob Thaysen

executive
#29

As I've said previously, and my view hasn't changed, the potential here is enormous, and what's happening in this area remains extremely, extremely robust. There's no reason I can see that this very strong expansion wouldn't keep going. Sure, it'll move around somewhat from one quarter to the next, but over a longer time frame, the possibilities here are extremely, extremely sound, and we're observing that in both oncology and genetic disease testing, as we noted earlier. What comes next is that you'll start examining new areas we haven't truly concentrated on at present, such as cardiovascular, neurodiseases, and other things; this will be a long term with a very strong growth opportunity.

Dan Brennan

analyst
#30

Thanks, that's great. I appreciate you fielding these. Perhaps just two or three. Regarding mid-throughput — Ankur, I believe you mentioned something while revising the guidance about mid-throughput patterns possibly being less strong. Could you elaborate on that? The market, perhaps competition, and then concerning the earnings increase tied to R&D expensing, does that apply only going forward, or does it reach back to the start of the year? I'm curious whether you've factored in the entire sum. The last item would be, could you remind us about the wider U.S. academic customer base? I know you've provided some detail previously. What is currently assumed in the full-year guidance from a revenue perspective year-over-year, and has the revised guidance altered that? Thank you.

Jacob Thaysen

executive
#31

I'll begin by addressing mid-throughput. To give some context, the majority of our high-throughput clients, whenever they buy an X, they do so in order to achieve high volume with high utilization, and they operate that way in a production-like logic. They recognize upon purchasing one that they intend to use it daily without interruption. If you examine the mid-throughput category, which is far more closely tied to the research space, I believe roughly 75% of that business — the 1K 2K business — sits there. These tend to be more project-based, and because of that, there's also a factor where some cautiousness gets built in by the various companies or even by academic institutions. They are delaying the choice to buy new instruments, and what we're observing is that the decision-making process is requiring more time. We're also noticing that although they continue running the project, a portion of that work is being sent out to service providers. The business remains, but it appears within the high-throughput segment. We do expect that once the macro environment shifts, we'll see some of those customers return and wish to bring some testing back in-house, because they feel they want to keep their samples within their own facilities. Meanwhile, the MiSeq i100 has been extremely successful here. Since our launch in late 2024, we placed over 500 instruments, and clearly it belongs to the low throughput area; given the capacity achievable with the MiSeq i100, it is reaching into what I'd describe as the lower end of the mid-throughput area. We're also observing momentum originating from that side. Lastly, you're correct, this space is where we encounter the most competition. That hasn't truly shifted; the dynamics in that space haven't changed during the past quarter. I wouldn't credit any of the softness you're currently seeing specifically to competition. That's broadly how I view things at the moment.

Ankur Dhingra

executive
#32

Right, absolutely. About the second portion of that question regarding the academia customer base — I'll take that. For that segment of the market, our guidance and expectations haven't shifted at all. From a business trend standpoint, what we observed in Q2 looked fairly comparable to what showed up in the later portion of Q1. On our expectation there, I think on the prior call we stated a 15% decline for the year in that part of the business. That remains unchanged.

Brian Blanchett

executive
#33

We appreciate you being with us on this call. A recording of today’s session will be posted in the Investor area of our site. That wraps up our discussion, and we hope to see you at the events we have coming up. Thanks.

Operator

operator
#34

That wraps up the call for today, and we appreciate everyone for joining in. You’re free to hang up now, and we hope the rest of your day is wonderful.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.